THE EFFECT OF PERCUTANEOUS CATHETER DRAINAGE COMBINED WITH SOMATOSTATIN ON INFLAMMATION AND PLASMA THROMBOXANE 2, PROSTACYCLIN I2 LEVELS IN PATIENTS WITH SEVERE PANCREATITIS.

Objective: Explore the effectiveness of ultrasound-guided percutaneous catheter drainage (PCD) combined with somatostatin in the treatment of severe pancreatitis (SAP) patients.

Methods: A retrospective study method was adopted to select 95 patients with SAP who were treated in our hospital from January 2018 to June 2022 for clinical research. Among them, 48 patients received routine treatment+somatostatin (control group), and other 47 patients received ultrasound guided PCD treatment on the basis of the control group (research group). The differences in the peripheral white blood cells (WBC), procalcitonin (PCT), interleukin-6 (IL-6), and Tumor Necrosis Factor- α(TNF- α), prostacyclin I2 (PGI2), plasma thromboxane 2 (TXA2), blood amylase, serum albumin (ALB), acute physiological function and chronic health score (APACHE II), sequential organ failure score (SOFA), and clinical efficacy were compared. The ICU treatment time, hospital stay, and incidence of complications were also recorded for the two groups of patients.

Results: Before treatment, there was no statistically significant difference in APACHE II score and SOFA score between the research group and the control group (P>0.05); The APACHE II scores of the research group after 14 days of treatment and 28 days of treatment were lower than those of the control group. The SOFA scores of the research group after 28 days of treatment were lower than those of the control group, and the differences were statistically significant (P<0.05); Before treatment, there was no statistically significant difference in WBC, PCT, IL-6, TNF-α, PGI2, TXA2, blood amylase, and ALB levels between the research group and control group (P>0.05); PCT, IL-6, TNF-α, TXA2 and blood amylase levels in the research group after 28 days of treatment were lower than that in the control group, and the differences were statistically significant (P<0.05); The ICU treatment time and hospitalization time of the research group were lower than those of the control group, and the differences were statistically significant (P<0.05); After 28 days of treatment, clinical efficacy evaluation was conducted, and the overall efficacy of the research group patients was better than that of the control group, with statistically significant differences (P<0.05); The complication rate of the research group was 27.66%, and that of the control group was 47.92%, which was significantly lower in the research group than in the control group (P<0.05).

Conclusion: Ultrasound guided PCD combined with somatostatin treatment for SAP patients can more effectively alleviate the degree of inflammatory response, effectively alleviate the severity of the patient's condition, reduce the occurrence of related complications, and improve clinical treatment effectiveness.